In a recent 13F filing, Henry Ellenbogen's Durable Capital disclosed a significant reduction in its holdings of BIO-TECHNE CORP (TECH). The report, which covers the quarter ending June 30, 2026, revealed an 88.74% decrease in the firm's position, from 4.46 million shares down to just over 500,000.
Investors should note that 13F filings are submitted with a delay, reflecting trades made in the prior quarter. This particular disclosure is notable as the reporting period closed just days after BIO-TECHNE announced on June 25, 2026, that it had agreed to be acquired by Merck KGaA for $73 per share. The timing suggests the sale may be related to the acquisition announcement, a common period for investors to de-risk their positions and realize gains.